Phase 1 Trials: Therapy, Not Just Science
Phase 1 trials should be considered therapeutic options for some patients.
All articles by Carlos Harrison
Confronting Racial Disparities in Prostate Cancer Survival Outcomes
African Americans have a 60% higher incidence of prostate cancer and are about 2 times more likely to die from the disease.
Can A Consortium of Hospitals Help To Reduce Drug Prices?
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Managing Adverse Events in the Era of Immunotherapy
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
Healthful Lifestyles and Cancer: Much More Than A Single Behavior
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
AI: Inroads Into Clinical Oncology
Novel algorithms may be able to diagnose and plan cancer treatments more effectively than humans, but it’s unclear if and when artificial intelligence will be integrated into clinical practice.
Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances
Access to treatment should be considered as important as the research leading to clinical improvements.
Cannabis for Cancer: An Uncertain Future
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
The Warburg Effect: Can Cancer Be Starved of Sugar?
A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.
Rare Cancer: An Underserved Area of Oncology
As more rare cancers are identified, the need for rethinking approaches to research will become greater.
-
Loading...
-
Loading...
Next post in General Oncology
